Entrada Therapeutics (TRDA) Non-cash Items (2020 - 2021)
Entrada Therapeutics (TRDA) recorded quarterly Non-cash Items of $26.7 million in Q4 2021, up 19479.55% quarter-over-quarter from $136520.0 in Q3 2021, and up 95813.02% on a YoY basis from N/an in Q4 2020.
Entrada Therapeutics (TRDA) Non-cash Items (2020 - 2021) Analysis & Trends
Entrada Therapeutics' Non-cash Items history runs 2 years deep, the most recent figure standing at $26.7 million for Q4 2021.
- In Q4 2021, Non-cash Items rose 95813.02% year-over-year to $26.7 million; the TTM figure through Dec 2021 stood at $26.7 million (up 95813.02% YoY), while the FY2021 annual figure was $26.7 million, up 95813.02% from the prior year.
- Non-cash Items was $26.7 million for Q4 2021 at Entrada Therapeutics, up from $136520.0 in the prior quarter.
- In the past five years, Non-cash Items ranged from a high of $26.7 million in Q4 2021 to a low of $27869.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Entrada Therapeutics | 295.36 Mn | 295.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 26.73 Mn |
| Dec 31, 2021 | 26.73 Mn |
| Sep 30, 2021 | 136,520.00 |
| Sep 30, 2021 | 136,520.00 |
| Dec 31, 2020 | 27,869.00 |
| Dec 31, 2020 | 27,869.00 |